Last reviewed · How we verify
breathing 100% oxygen
breathing 100% oxygen is a Small molecule drug developed by Medical University of Vienna. It is currently in Phase 1 development.
Breathing 100% oxygen is essential for cellular homeostasis, a fundamental process necessary for maintaining life. This process has been studied in various clinical trials, including those for resuscitation of late-preterm infants and treatment of conditions such as asphyxia and mild cognitive impairment.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | breathing 100% oxygen |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Relative bradycardia
Key clinical trials
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial. (PHASE4)
- Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer (PHASE4)
- High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways (NA)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- The Effect of Role Differences on Learning and Self-Assessment in Simulation-Based Life Support Training Among Dental Students (NA)
- Optimal Number of Hyperbaric Oxygen Treatments for Carbon Monoxide Poisoning (NA)
- Oxygen Reserve Index in Laparoscopic Colorectal Surgery
- Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- breathing 100% oxygen CI brief — competitive landscape report
- breathing 100% oxygen updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI
Frequently asked questions about breathing 100% oxygen
What is breathing 100% oxygen?
Who makes breathing 100% oxygen?
What development phase is breathing 100% oxygen in?
What are the side effects of breathing 100% oxygen?
Related
- Manufacturer: Medical University of Vienna — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing